Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
JNJ Stock Forecast 2026-2027
$226.16
Current Price
$555.94B
Market Cap
Buy 14
Hold 10
Sell 1
Wall St Analyst Ratings
Distance to JNJ Price Targets
+26.0%
To High Target of $285.00
+13.4%
To Median Target of $256.50
-31.5%
To Low Target of $155.00
JNJ Price Momentum
-5.2%
1 Week Change
-3.9%
1 Month Change
+43.4%
1 Year Change
+9.3%
Year-to-Date Change
-10.2%
From 52W High of $251.71
+54.8%
From 52W Low of $146.12
📊 TOP ANALYST CALLS
Did JNJ Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Johnson & Johnson is one of their latest high-conviction picks.
Latest JNJ Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, JNJ has a bullish consensus with a median price target of $256.50 (ranging from $155.00 to $285.00). The overall analyst rating is Buy (7.7/10). Currently trading at $226.16, the median forecast implies a 13.4% upside. This outlook is supported by 14 Buy, 10 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Rick Wise at Stifel, suggesting a 31.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JNJ Analyst Ratings
14
Buy
10
Hold
1
Sell
JNJ Price Target Range
Low
$155.00
Average
$256.50
High
$285.00
Current: $226.16
Latest JNJ Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JNJ.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2026 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $263.00 |
| Apr 15, 2026 | Stifel | Rick Wise | Hold | Maintains | $250.00 |
| Apr 15, 2026 | Barclays | Matt Miksic | Equal-Weight | Maintains | $255.00 |
| Apr 10, 2026 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $267.00 |
| Apr 8, 2026 | TD Cowen | Michael Nedelcovych | Buy | Assumes | $250.00 |
| Mar 30, 2026 | RBC Capital | Shagun Singh | Outperform | Reiterates | $255.00 |
| Mar 19, 2026 | Barclays | Matt Miksic | Equal-Weight | Maintains | $234.00 |
| Mar 17, 2026 | HSBC | Morten Herholdt | Buy | Maintains | $280.00 |
| Mar 11, 2026 | Citigroup | Joanne Wuensch | Buy | Maintains | $274.00 |
| Mar 5, 2026 | JP Morgan | Chris Schott | Neutral | Maintains | $250.00 |
| Feb 3, 2026 | RBC Capital | Shagun Singh | Outperform | Maintains | $255.00 |
| Jan 28, 2026 | Morgan Stanley | Terence Flynn | Overweight | Upgrade | $262.00 |
| Jan 27, 2026 | Freedom Capital Markets | Ilya Zubkov | Hold | Maintains | $220.00 |
| Jan 27, 2026 | Freedom Broker | Hold | Maintains | $N/A | |
| Jan 23, 2026 | Guggenheim | Vamil Divan | Buy | Maintains | $240.00 |
| Jan 22, 2026 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $200.00 |
| Jan 22, 2026 | Scotiabank | Louise Chen | Sector Outperform | Maintains | $265.00 |
| Jan 22, 2026 | Citigroup | Joanne Wuensch | Buy | Maintains | $250.00 |
| Jan 22, 2026 | TD Cowen | Joshua Jennings | Buy | Maintains | $250.00 |
| Jan 22, 2026 | B of A Securities | Tim Anderson | Neutral | Maintains | $221.00 |
Johnson & Johnson (JNJ) Competitors
The following stocks are similar to Johnson & Johnson based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Johnson & Johnson (JNJ) Financial Data
Johnson & Johnson has a market capitalization of $555.94B with a P/E ratio of 21.2x. The company generates $96.36B in trailing twelve-month revenue with a 21.8% profit margin.
Revenue growth is +9.9% quarter-over-quarter, while maintaining an operating margin of +26.7% and return on equity of +32.9%.
Valuation Metrics
Market Cap
$555.94B
Enterprise Value
$593.58B
P/E Ratio
21.2x
PEG Ratio
0.4x
Price/Sales
5.9x
Growth & Margins
Revenue Growth (YoY)
+9.9%
Gross Margin
+67.6%
Operating Margin
+26.7%
Net Margin
+21.8%
EPS Growth
-52.4%
Financial Health
Cash/Price Ratio
+3.7%
Current Ratio
1.0x
Debt/Equity
60.5x
ROE
+32.9%
ROA
+13.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Johnson & Johnson (JNJ) Business Model
About Johnson & Johnson
What They Do
Healthcare products research, development, and sales.
Business Model
The company operates through two main segments: Innovative Medicine and MedTech. It generates revenue by selling pharmaceutical products and medical devices, addressing various therapeutic areas and health challenges globally. With a strong emphasis on research and development, it invests heavily in innovative solutions, contributing to significant sales growth.
Additional Information
Founded in 1887 and headquartered in New Brunswick, New Jersey, Johnson & Johnson employs around 139,800 people and reported $94.2 billion in revenue with a 5.3% operational growth. The company is noted for its solid financials, including a 2.1% dividend yield and a reputation as a Dividend King in healthcare. Its diverse product portfolio and global distribution network ensure stable cash flows.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
138,200
CEO
Mr. Joaquin Duato
Country
United States
IPO Year
1970
Website
www.jnj.comJohnson & Johnson (JNJ) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
AbbVie stock trades below key SMAs, signaling weakness, but strong Skyrizi and Rinvoq growth and a robust pipeline could support a rebound.
Apr 17, 2026
By Kinjel Shah
Analyst Blog
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Apr 15, 2026
By Zacks Equity Research
Tale of the Tape
Company News for Apr 15, 2026
Companies In The News Are: JNJ, WFC, ACI, NVO.
Apr 15, 2026
By Zacks Equity Research
Corporate Summary
Latest News
Quick Summary
Johnson & Johnson (JNJ) reported better-than-expected Q1 results, surpassing earnings and sales estimates despite Stelara's loss of exclusivity. Key drugs like Darzalex, Tremfya, and Erleada excelled.
Why It Matters
Johnson & Johnson's strong Q1 performance and resilient drug sales amid LOE for Stelara indicate robust growth potential, enhancing investor confidence in the company's future profitability.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Johnson & Johnson introduced CARTOSOUND SONATA, a new innovation for arrhythmia care, powered by CARTO, at the HRS 2026 conference in Irvine, California.
Why It Matters
Johnson & Johnson's CARTOSOUND SONATA launch highlights advancements in arrhythmia care, potentially boosting market share and revenue in a growing healthcare sector, impacting investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Johnson & Johnson has obtained European CE Mark approval for its new ETHICON™ 4000 Stapler, indicating compliance with EU safety standards.
Why It Matters
The CE Mark approval for Johnson & Johnson's ETHICON™ 4000 Stapler indicates regulatory validation, potentially boosting sales and market share in Europe, impacting revenue growth positively.
Source: Business Wire
Market Sentiment:
Neutral
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
18 hours ago
Quick Summary
Johnson & Johnson (NYSE: JNJ) will participate in the RBC Capital Markets Global Healthcare Conference on May 19, 2026, with a Fireside Chat at 11:30 a.m. ET, accessible via their investor website.
Why It Matters
Johnson & Johnson's participation in the RBC Capital Markets Global Healthcare Conference signals potential insights into its strategic direction and financial health, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Earned income has a limit, while passive income from dividend stocks provides consistent cash flow regardless of market conditions or employment status.
Why It Matters
The distinction highlights the stability of passive income from dividends, which can provide consistent cash flow regardless of market conditions, appealing to risk-averse investors.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Johnson & Johnson's Q1 2026 earnings surpassed expectations, but investor reaction was muted.
Why It Matters
Johnson & Johnson's Q1 2026 earnings beat expectations but lackluster investor reaction may signal concerns about future growth or valuation, impacting stock performance and market sentiment.
Source: The Motley Fool
Market Sentiment:
Neutral
Frequently Asked Questions About JNJ Stock
What is Johnson & Johnson's (JNJ) stock forecast for 2026?
Based on our analysis of 34 Wall Street analysts, Johnson & Johnson (JNJ) has a median price target of $256.50. The highest price target is $285.00 and the lowest is $155.00.
Is JNJ stock a good investment in 2026?
According to current analyst ratings, JNJ has 14 Buy ratings, 10 Hold ratings, and 1 Sell ratings. The stock is currently trading at $226.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for JNJ stock?
Wall Street analysts predict JNJ stock could reach $256.50 in the next 12 months. This represents a 13.4% increase from the current price of $226.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Johnson & Johnson's business model?
The company operates through two main segments: Innovative Medicine and MedTech. It generates revenue by selling pharmaceutical products and medical devices, addressing various therapeutic areas and health challenges globally. With a strong emphasis on research and development, it invests heavily in innovative solutions, contributing to significant sales growth.
What is the highest forecasted price for JNJ Johnson & Johnson?
The highest price target for JNJ is $285.00 from at , which represents a 26.0% increase from the current price of $226.16.
What is the lowest forecasted price for JNJ Johnson & Johnson?
The lowest price target for JNJ is $155.00 from Rick Wise at Stifel, which represents a -31.5% decrease from the current price of $226.16.
What is the overall JNJ consensus from analysts for Johnson & Johnson?
The overall analyst consensus for JNJ is bullish. Out of 34 Wall Street analysts, 14 rate it as Buy, 10 as Hold, and 1 as Sell, with a median price target of $256.50.
How accurate are JNJ stock price projections?
Stock price projections, including those for Johnson & Johnson, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 8:15 AM UTC